L-carnitine supplementation for rheumatoid arthritis patients
Official title: Effect of L-carnitine Supplementation on Disease Activity in Rheumatoid Arthritis Patients
Run by German University in Cairo · NCT06753565 · Data updated 2026-11-12
This study is testing if adding L-carnitine to the usual treatments can help adults with rheumatoid arthritis feel better and improve their joint health.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | German University in Cairo Academic / other |
| Locations | 1 site (Cairo, Demerdash) |
| Status | Recruiting |
| Started | December 31, 2024 |
| Main results expected | June 2025 |
| Study ends | June 2025 |
| Registry record updated | January 7, 2025 |
| Trial ID | NCT06753565 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-60 diagnosed with rheumatoid arthritis for at least six months who are currently on stable DMARD therapy but still experience active disease.
✕Probably not a fit
Patients who are pregnant, have liver or kidney dysfunction, or are taking medications that interact with carnitine may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effects of L-carnitine as an add-on therapy for patients with rheumatoid arthritis (RA) who are already receiving conventional disease-modifying anti-rheumatic drugs (DMARDs). It aims to improve patient outcomes by assessing the anti-inflammatory and antioxidant properties of L-carnitine. Eligible participants are adults aged 18-60 with active RA despite stable DMARD treatment for at least six months. The study will measure the impact of L-carnitine on disease activity and overall joint health.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for managing rheumatoid arthritis symptoms and improving patient quality of life.
How similar studies have gone: While the use of L-carnitine in other conditions has shown promise, this specific application in rheumatoid arthritis is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age between 18-60 years old * diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months * enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study * active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2) * patient or legal representative should sign informed consent Exclusion Criteria: * pregnant or lactating female * patients with liver dysfunction (\>1.5x the upper limit of normal value for ALT \& AST) * Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl) * Patients with any active infection or concurrent malignancy * patients with uncontrolled medical conditions or other rheumatic diseases * patients currently taking drugs that could interact with carnitine like: warfarin
Where it's running
-
Demerdash hospital
Cairo, Demerdash, Egypt Recruiting
Study contacts
- Study coordinator: Mariam Ehab, Master
- Email: mariam.ehab-azmy@guc.edu.eg
- Phone: +2001223360548
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.